`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF MASSACHUSETTS
`
`
`
`
`TEVA PHARMACEUTICALS
`
`
`INTERNATIONAL GMBH and
`TEVA PHARMACEUTICALS USA, INC.
`
`
`
`
`
`
`
`Plaintiffs,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`v.
`
`
`
`
`
`
`
`
`ELI LILLY AND COMPANY
`
`
`
`
`
`
`
`
`
`
`
`Defendant.
`
`
`
`
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`
`
`
`
`Case No. 1:18-cv-12029-ADB
`
`
`
`
`DECLARATION OF RYAN P. O’QUINN IN SUPPORT OF DEFENDANT ELI LILLY
`AND COMPANY’S DAUBERT MOTION TO PARTIALLY EXCLUDE TESTIMONY
`OF DR. ELAN RUBINSTEIN AND DR. MARK BERKMAN
`
`
`I, Ryan P. O’Quinn, declare as follows:
`
`
`
`1.
`
`I am a partner with Finnegan, Henderson, Farabow, Garrett & Dunner, LLP,
`
`counsel for Eli Lilly and Company (Lilly) in this matter. I am licensed to practice in the
`
`Commonwealth of Virginia and the District of Columbia and am admitted pro hac vice in the
`
`above-captioned case. I have personal knowledge of the matters set forth herein, and if called
`
`upon would testify as follows.
`
`2.
`
`Attached hereto as Exhibit A is a true and correct excerpted copy of the Opening
`
`Expert Report of Elan B. Rubinstein, Pharm.D, M.P.H., dated September 15, 2021.
`
`3.
`
`Attached hereto as Exhibit B is a true and correct excerpted copy of the Rebuttal
`
`Expert Report of Laura E. Happe, Pharm.D, M.P.H., dated October 28, 2021.
`
`4.
`
`Attached hereto as Exhibit C is a true and correct excerpted copy of the
`
`transcript of the deposition of Elan B. Rubinstein, Pharm.D, M.P.H., dated January 14, 2022.
`
`
`
`Case 1:18-cv-12029-ADB Document 313 Filed 03/28/22 Page 2 of 4
`
`5.
`
`Attached hereto as Exhibit D is a true and correct excerpted copy of the Reply
`
`Expert Report of Elan B. Rubinstein, Pharm.D, M.P.H., dated December 7, 2021.
`
`6.
`
`Attached hereto as Exhibit E is a true and correct copy of a document produced
`
`by Teva in this litigation bearing Bates numbers TEVA_FREM_002987369–
`
`TEVA_FREM_002987379.
`
`7.
`
`Attached hereto as Exhibit F is a true and correct excerpted copy of the Reply
`
`Report of Mark P. Berkman, dated December 7, 2021.
`
`8.
`
`Attached hereto as Exhibit G is a true and correct excerpted copy of the Expert
`
`Report of Mark P. Berkman, dated September 16, 2021.
`
`9.
`
`Attached hereto as Exhibit H is a true and correct excerpted copy of the
`
`transcript of the deposition of Mark P. Berkman, Ph.D., dated January 18, 2022.
`
`10.
`
`Attached hereto as Exhibit I is a true and correct copy of the webpage “Get
`
`Savings Offer | AJOVY® (fremanezumab-vfrm) injection” located at the URL
`
`https://www.ajovy.com/savings/; last accessed March 23, 2022.
`
`11.
`
`Attached hereto as Exhibit J is a true and correct copy of a document produced
`
`by Lilly in this litigation bearing Bates numbers LLY-GALCA-00706061–LLY-GALCA-
`
`00706109.
`
`12.
`
`Attached hereto as Exhibit K is a true and correct copy of a document produced
`
`by Teva in this litigation bearing Bates numbers TEVA_FREM_004789029–
`
`TEVA_FREM_004789059.
`
`13.
`
`Attached hereto as Exhibit L is a true and correct copy of the webpage “U.S.
`
`Bureau of Labor Statistics, CPI for All Urban Consumers (CPI-U)” located at the URL
`
`2
`
`
`
`Case 1:18-cv-12029-ADB Document 313 Filed 03/28/22 Page 3 of 4
`
`https://data.bls.gov/timeseries/CUUR0000SA0&output_view=pct_12mths; last accessed March
`
`23, 2022.
`
`14.
`
`Attached hereto as Exhibit M is a true and correct excerpted copy of the
`
`transcript of the deposition of Laura Steele, dated August 4, 2021.
`
`15.
`
`Attached hereto as Exhibit N is a true and correct copy of a document produced
`
`by Lilly in this litigation bearing Bates numbers LLY-GALCA-00690565– LLY-GALCA-
`
`00690585.
`
`16.
`
`Attached hereto as Exhibit O is a true and correct copy of a document entitled
`
`Teva Full Product Catalog, dated January 10, 2022, introduced as Exhibit 13 in the January 14,
`
`2022 deposition of Elan Rubinstein.
`
`17.
`
`Exhibits A-H, J, K, M, and N to this declaration are subject to Defendant Lilly’s
`
`Assented-To Motion for Leave to Impound Confidential Portions of Defendant’s Memoranda
`
`and Certain Exhibits (ECF No. 284; granted at ECF No. 285) and will be provisionally filed
`
`under seal.
`
`18.
`
`Complete copies of any excerpted documents identified above will be provided to
`
`the Court upon request.
`
` declare under the penalty of perjury that the foregoing is true and correct to the best of
`
`
`
` I
`
`my knowledge.
`
`Executed on this 28th day of March, 2022, in Ashburn, Virginia.
`
` /s/ Ryan P. O’Quinn
`Ryan P. O’Quinn
`
`
`
`
`
`
`3
`
`
`
`Case 1:18-cv-12029-ADB Document 313 Filed 03/28/22 Page 4 of 4
`
`
`CERTIFICATE OF SERVICE
`
`I, Andrea L. Martin, hereby certify that this document filed through the ECF system will
`
`
`
`be sent electronically to the registered participants as identified on the Notice of Electronic Filing
`
`(NEF) and paper copies will be sent to those indicated as non-registered participants on March
`
`28, 2022.
`
`
`
`/s/Andrea L. Martin
`Andrea L. Martin
`
`
`
`
`
`
`
`